NCT05722951View on ClinicalTrials.gov

Metformin Efficacy and Safety in Epileptic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

June 20, 2024

Study Completion Date

June 20, 2024

Conditions
Epilepsy
Interventions
DRUG

Levetiracetam &/or sodium valproate

levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months

DRUG

Metformin

metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months

Trial Locations (1)

Unknown

Omnia Ashraf Abd El Aziz Ahmed Kotb, Alexandria

All Listed Sponsors
lead

Tanta University

OTHER